The latest news from academia, regulators
research labs and other things of interest
Posted: Sep 21, 2010
MagForce Nanotechnologies AG Announces Publication of Clinical Data Using Nanoparticles for the Treatment of Recurrent Glioblastoma Multiforme
(Nanowerk News) MagForce Nanotechnologies AG announced today the
publication of clinical data from a clinical study examining the safety and efficacy of
intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with
external beam radiotherapy in patients with recurrent glioblastoma multiforme.
The study data, published on September 20, 2010 in the Journal of Neuro-Oncology, is
available online on the Journal's website at http://www.springerlink.com/content/u27ll42612302123/ or
"This data publication provides detailed insight into the clinical data that supported
our recent regulatory approval for Nano-Cancer® therapy. Through the publication, we are
pleased to address a wider international audience and give them insight into MagForce's
novel concept of using nanotechnology for the treatment of cancer," said Dr. Peter
Heinrich, CEO of MagForce Nanotechnologies AG. "We are currently focused on
strengthening our commercialization team and infrastructures in preparation for the next
strategic steps, including the planned Q1 2011 product launch in Germany, additional
clinical trials, and further internationalization."
Nano-Cancer® therapy uses iron oxide nanoparticles, which are injected into the tumor
and, due to their special coating, aggregate and remain in place. The patient is then
placed into a magnetic field applicator. Through the application of an alternating
magnetic field, the nanoparticles begin to oscillate, produce warmth, and damage or kill
the tumor tissue.
About MagForce Nanotechnologies
MagForce Nanotechnologies AG is a leader in the area of nanotechnology-based cancer
treatment. The proprietary procedure which it has developed, Nano-Cancer therapy,
enables the targeted treatment of solid tumors through the intratumoral release of heat
from magnetic nanoparticles. Its products used in the therapy, NanoTherm and
NanoActivator, have received EU-wide regulatory approval as medical devices for the
treatment of brain tumors.